For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- New Orphan Drugs, Medical Device Announced
May 28, 2001
- Rituximab Recommended for Approval: CDFS
May 21, 2001
- Korosho Issues Notifications of Revision of Specifications and Test Method Guidelines
May 21, 2001
- Average Household's Healthcare Spending Down in FY2000
May 21, 2001
- Preparations in Progress for Advent of CTD in July
May 21, 2001
- Japanese Global Strategy Update (2)
May 21, 2001
- Keidanren, Nikkeiren to Propose Independent Health Insurance for Elderly
May 21, 2001
- Snow Brand Milk to Transfer Its Pharma Business to Daiichi
May 21, 2001
- Over 40% of Doctors Recognize Usefulness of Large-scale Trials: Survey
May 21, 2001
- Fujisawa to Transfer Animal Health Business to Schering-Plough
May 21, 2001
- Increasing Number of Firms Try to Obtain Information on Competitors Based on Information Access Law
May 21, 2001
- Shionogi USA Established
May 21, 2001
- REGULATORY NEWS IN BRIEF
May 21, 2001
- Santen Ties Up with PDI for Levofloxacin
May 21, 2001
- JMA to Start Monitoring Medical Facilities' Business Performance
May 21, 2001
- SSP, Nihon Tenganyaku to Jointly Research Antifungal Eye Drop
May 21, 2001
- \240,000 Necessary per Month forNursing Care: Survey Respondents
May 21, 2001
- Kissei Completes Therapeutic Nutritive Food Business Center
May 21, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2001
- Ethical Drugs Achieve 2.5% Growth in FY2000
May 21, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…